Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer)

INTRODUCTION: This single-arm phase II trial aimed to evaluate a stop-and-go strategy with cisplatin-based chemotherapy and bevacizumab in advanced non-squamous non-small cell lung cancer (NSCLC). METHODS: Patients were initially treated with three cycles of pemetrexed, cisplatin plus bevacizumab (s...

Descripción completa

Detalles Bibliográficos
Autores principales: Bennouna, Jaafar, Barlesi, Fabrice, Do, Pascal, Dumont, Patrick, Cadranel, Jacques, Debieuvre, Didier, Hilgers, Werner, Molinier, Olivier, Quoix, Elisabeth, Raimbourg, Judith, Langlais, Alexandra, Morin, Franck, Souquet, Pierre-Jean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069905/
https://www.ncbi.nlm.nih.gov/pubmed/30094074
http://dx.doi.org/10.1136/esmoopen-2018-000394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069905/
https://www.ncbi.nlm.nih.gov/pubmed/30094074
http://dx.doi.org/10.1136/esmoopen-2018-000394

Ejemplares similares